Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio-Rad Acquires Cell Sorting System from Propel Labs

Published: Thursday, November 01, 2012
Last Updated: Thursday, November 01, 2012
Bookmark and Share
The simplicity of operation and price point of the S3 Cell Sorter will make cell sorting more accessible to new labs and core facilities that previously could not afford or support such an instrument.

What are the terms of the agreement?

Under the terms of agreement, Bio-Rad has acquired Propel Labs’ Avalon™ system, an automated, easy-to-use benchtop cell sorter. The new system will be provided and supported exclusively under the Bio-Rad brand as the S3 Cell Sorter.

Why did Bio-Rad acquire the Avalon system?S3CellSorter_ad_v1.gif

Cell sorting systems are used primarily in flow cytometry core facilities at academic, government, and industrial research institutions due to the size, high cost, and complexity of operation and maintenance. Bio-Rad and Propel Labs recognized the market need for a robust, low cost cell sorter to handle the workload challenges facing core facilities today. Additionally, the simplicity of operation and price point will make cell sorting more accessible to new labs and core facilities that previously could not afford or support such an instrument.

What does Tidar Sadeh, Propel Labs President and CEO, have to say about the agreement?

“We welcome the opportunity to partner with Bio-Rad to commercialize the S3 Cell Sorter. This cell sorting platform establishes a new benchmark in terms of price, performance, and ease-of-use and meets the needs of researchers working in cell biology today.”

Tell me about the S3 Cell Sorter (formerly the Avalon system).

Bio-Rad’s S3 Cell Sorter uses established jet-in-air technology and is equipped with one or two lasers and up to four fluorescent detectors as well as forward and side scatter detectors.

What are the advantages of the S3 Cell Sorter?

•    The new ProDrop™ technology automates setup and calibration in less than 30 minutes, which allows samples to be sorted at high speeds while maintaining sensitivity and high purity.

•    The completely internalized fluidics and temperature control system enable a compact size to fit in any lab.

•    Each S3 Cell Sorter is shipped with an intuitive, lab friendly ProAnalyzer™ software package. Installation and on-site training can be completed within three days.

What is Propel Labs?

Propel Labs, Inc. is a privately held biotechnology instrumentation company headquartered in Fort Collins, CO USA. Its principals helped develop the MoFlo™ cell sorter and the CyAn™ analyzer. The company focuses on the customer by quickly delivering innovative products and enhancing their research to advance patient care. For more information, visit www.propel-labs.com.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Researchers Develop Rapid, Cost-Effective Early Detection Method for Organ Transplant Injury
Chronix Biomedical and transplant expert Prof. Oellerich use Droplet Digital™ PCR to quantify early rejection biomarker.
Thursday, August 29, 2013
New Biomarker Could Reveal Alzheimer's Disease Years Before Onset
A new study has reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD).
Wednesday, August 14, 2013
Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits
Partnership to commercialize multiplex biomarker kits for life science research.
Wednesday, August 01, 2012
Bio-Rad Introduces new Pro-Human Diabetes Assay Panel
The Company has launched new Bio-Plex Pro™ Human Diabetes Assay Panels for its Bio-Plex® suspension array system.
Tuesday, June 24, 2008
Bio-Rad Announces Web Seminar Series
Web seminar series area includes Spectroscopy, Chromatography, ADME/Tox and Metabolomics.
Friday, May 05, 2006
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!